BiotechTube
ORCA Therapeutics

ORCA Therapeutics

Leiden, Netherlands· Est.
orca-therapeutics.nl
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

ORCA Therapeutics is a private, pre-revenue biotech developing novel oncolytic virus therapies for prostate cancer. The company's core technology, the T1 platform, aims to create adenoviruses with significantly higher oncolytic potency compared to current standards. Its lead program, ORCA-010, is in a Phase I/IIa dose-escalation study in Canada for treatment-naïve, localized prostate cancer patients, representing a direct intratumoral approach in an early-stage setting. The company leverages partnerships and has received Horizon2020 grant funding to advance its research.

OncologyProstate Cancer

Technology Platform

Proprietary T1 platform for engineering oncolytic adenoviruses with claimed up to 10,000-fold higher potency compared to current standards.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

A successful oncolytic virus for localized prostate cancer could address major unmet needs in preserving quality of life and improving outcomes, tapping into a large and growing oncology market.
Positive clinical data could attract partnership interest from larger oncology-focused biopharma companies seeking novel immuno-oncology assets.

Risk Factors

High clinical development risk as a single-asset company; the intratumoral route and novel mechanism may face challenges in clinical efficacy and eventual adoption.
The company will require significant additional financing to progress beyond its current early-stage trial.

Competitive Landscape

The oncolytic virus space is competitive, with approved agents like T-VEC (talimogene laherparepvec) for melanoma and others in development. However, ORCA's focus on ultra-high potency adenoviruses and the specific indication of early, localized prostate cancer represents a more specialized and less crowded niche.

More companies in Netherlands →